{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:44:21Z","timestamp":1792806261976,"version":"4.5.0"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is characterized by fast tumor progression and diagnosis at advanced, inoperable stages. Previous studies could demonstrate an involvement of miR-192-5p in epigenetic regulation of visceral carcinomas. Due to contradictory results, however, the clinical utility of miR-192-5p in PDAC has yet to be determined. MiR-192-5p expression was analyzed by RT-qRT-PCR in human PDAC and benign tissue (n = 78), blood serum (n = 81) and serum exosomes (n = 74), as well as in PDAC cell lines (n = 5), chemoresistant cell clones (n = 2), and pancreatic duct cell line H6c7. Analysis of EMT-associated (epithelial-to-mesenchymal transition) proteins was performed by immunohistochemistry and Western blot. MiR-192-5p was deregulated in PDAC as compared to healthy controls (HCs), with downregulation in macrodissected tissue (p &lt; 0.001) and upregulation in blood serum of PDAC UICC (Union for International Cancer Control) stage IV (p = 0.016) and serum exosomes of PDAC UICC stages II to IV (p &lt; 0.001). MiR-192-5p expression in tumor tissue was significantly lower as compared to corresponding peritumoral tissue (PDAC UICC stage II: p &lt; 0.001; PDAC UICC stage III: p = 0.024), while EMT markers ZEB1 and ZEB2 were more frequently expressed in tumor tissue as compared to peritumoral tissue, HCs, and chronic pancreatitis. Tissue-derived (AUC of 0.86; p &lt; 0.0001) and exosomal (AUC of 0.83; p = 0.0004) miR-192-5p could differentiate between PDAC and HCs with good accuracy. Furthermore, high expression of miR-192-5p in PDAC tissue of curatively resected PDAC patients correlated with prolonged overall and recurrence-free survival in multivariate analysis. In vitro, miR-192-5p was downregulated in gemcitabine-resistant cell clones of AsPC-1 (p = 0.029). Transient transfection of MIA PaCa-2 cells with miR-192-5p mimic resulted in downregulation of ZEB2. MiR-192-5p seems to possess a tumor-suppressive role and high potential as a diagnostic and prognostic marker in PDAC.<\/jats:p>","DOI":"10.3390\/cancers12061693","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T10:36:54Z","timestamp":1593081414000},"page":"1693","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma"],"prefix":"10.3390","volume":"12","author":[{"given":"Isabelle","family":"Flammang","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1 (W1), 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-7664","authenticated-orcid":false,"given":"Moritz","family":"Reese","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1 (W1), 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7177-4105","authenticated-orcid":false,"given":"Anda","family":"Str\u00f6se","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1 (W1), 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1 (W1), 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-2137","authenticated-orcid":false,"given":"Johannes","family":"Eble","sequence":"additional","affiliation":[{"name":"Department of Physiological Chemistry and Pathobiochemistry, University of Muenster, Waldeyerstrasse 15, 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Dhayat","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1 (W1), 48149 Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s13277-013-1033-3","article-title":"Biomarkers for pancreatic cancer: Promising new markers and options beyond CA 19-9","volume":"34","author":"Ballehaninna","year":"2013","journal-title":"Tumor Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.addr.2014.10.020","article-title":"Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer","volume":"81","author":"Rachagani","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2016.117","article-title":"Non-coding RNAs as drug targets","volume":"16","author":"Matsui","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dhayat, S.A., Traeger, M.M., Rehkaemper, J., Stroese, A.J., Steinestel, K., Wardelmann, E., Kabar, I., and Senninger, N. (2018). Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma. Cancers, 10.","DOI":"10.3390\/cancers10090328"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/ncb3513","article-title":"The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer","volume":"19","author":"Krebs","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.gastro.2013.10.010","article-title":"MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression","volume":"146","author":"Frampton","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dhayat, S.A., Mardin, W.A., Seggewiss, J., Strose, A.J., Matuszcak, C., Hummel, R., Senninger, N., Mees, S.T., and Haier, J. (2015). MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143755"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jama.2013.284664","article-title":"MicroRNA biomarkers in whole blood for detection of pancreatic cancer","volume":"311","author":"Schultz","year":"2014","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/ijc.30291","article-title":"The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer","volume":"139","author":"Johansen","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri855","article-title":"Exosomes: Composition, biogenesis and function","volume":"2","author":"Thery","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbcan.2018.11.001","article-title":"Functions and clinical implications of exosomes in pancreatic cancer","volume":"1871","author":"Qian","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1477-7819-11-219","article-title":"Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma","volume":"11","author":"Que","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1002\/ijc.29324","article-title":"Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity","volume":"136","author":"Madhavan","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2017.02.019","article-title":"A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer","volume":"393","author":"Lai","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"77028","DOI":"10.18632\/oncotarget.20332","article-title":"Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Goto, T., Fujiya, M., Konishi, H., Sasajima, J., Fujibayashi, S., Hayashi, A., Utsumi, T., Sato, H., Iwama, T., and Ijiri, M. (2018). An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4006-5"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jhbp.524","article-title":"Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma","volume":"25","author":"Takahasi","year":"2018","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.gene.2018.06.037","article-title":"Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis","volume":"673","author":"Zhou","year":"2018","journal-title":"Gene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1002\/cam4.2145","article-title":"Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis","volume":"8","author":"Zou","year":"2019","journal-title":"Cancer Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Reese, M., Flammang, I., Yang, Z., and Dhayat, S.A. (2020). Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma. Cancers, 12.","DOI":"10.3390\/cancers12010197"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3892\/or.2013.2420","article-title":"Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma","volume":"30","author":"Zhao","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1158\/0008-5472.CAN-15-0390","article-title":"Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression","volume":"76","author":"Botla","year":"2016","journal-title":"Cancer Res."},{"key":"ref_32","first-page":"6947","article-title":"MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1","volume":"15","author":"Zhou","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s13577-018-0201-6","article-title":"MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1","volume":"31","author":"Ji","year":"2018","journal-title":"Hum. Cell"},{"key":"ref_34","first-page":"30","article-title":"Evaluation of microRNA-9 and -192 expression levels as biomarkers in patients suffering from breast cancer","volume":"12","author":"Tavakolian","year":"2020","journal-title":"Biomed. Rep."},{"key":"ref_35","first-page":"1667","article-title":"MicroRNA192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1","volume":"42","author":"Chen","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_36","first-page":"1010428317695018","article-title":"Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma","volume":"39","author":"Sasikala","year":"2017","journal-title":"Tumour Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19619","DOI":"10.1038\/s41598-019-56018-5","article-title":"miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44","volume":"9","author":"Zou","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cam4.973","article-title":"A novel serum microRNA signature to screen esophageal squamous cell carcinoma","volume":"6","author":"Huang","year":"2017","journal-title":"Cancer Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12957-020-1798-y","article-title":"MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K\/AKT pathway","volume":"18","author":"Huang","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000496206","article-title":"miR-192 Is Overexpressed and Promotes Cell Proliferation in Prostate Cancer","volume":"28","author":"Chen","year":"2019","journal-title":"Med. Princ. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tseng, H.W., Li, S.C., and Tsai, K.W. (2019). Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression. Cancers, 11.","DOI":"10.3390\/cancers11020209"},{"key":"ref_42","first-page":"1753","article-title":"MicroRNA192 acts as a tumor suppressor in colon cancer and simvastatin activates miR192 to inhibit cancer cell growth","volume":"19","author":"Zheng","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_43","first-page":"1794","article-title":"Metabolites of intestinal microflora upregulate miR-192-5p to suppress proliferation of colon cancer cells via RhoA-ROCK-LIMK2 pathway","volume":"24","author":"Huang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.3892\/or.2015.4258","article-title":"Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K\/Akt signaling pathway","volume":"34","author":"Jin","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7150\/jca.25814","article-title":"MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901\/DDP cells","volume":"10","author":"Xie","year":"2019","journal-title":"J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/kjm2.12004","article-title":"miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A","volume":"35","author":"Zhang","year":"2019","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/PAI.0000000000000296","article-title":"MicroRNA-192-5p Promote the Proliferation and Metastasis of Hepatocellular Carcinoma Cell by Targeting SEMA3A","volume":"25","author":"Li","year":"2017","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kumar, S., Sharawat, S.K., Ali, A., Gaur, V., Malik, P.S., Mohan, A., and Guleria, R. (2020). Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Curr. Probl. Cancer, 100540.","DOI":"10.1016\/j.currproblcancer.2020.100540"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3892\/or.2013.2960","article-title":"Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma","volume":"31","author":"Zhang","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1038\/onc.2013.478","article-title":"MicroRNA-192 suppresses liver metastasis of colon cancer","volume":"33","author":"Geng","year":"2014","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1093\/nar\/gki965","article-title":"SIP1\/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions","volume":"33","author":"Vandewalle","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref_52","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"updated-by":[{"DOI":"10.3390\/cancers16162825","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000}}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1693\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:38:58Z","timestamp":1754260738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061693"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061693","relation":{"correction":[{"id-type":"doi","id":"10.3390\/cancers16162825","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}